Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

被引：0

作者：

Yeon Hee Park

Seock-Ah Im

Kyunghee Park

Ji Wen

Kyung-Hun Lee

Yoon-La Choi

Won-Chul Lee

Ahrum Min

Vinicius Bonato

Seri Park

Sripad Ram

Dae-Won Lee

Ji-Yeon Kim

Su Kyeong Lee

Won-Woo Lee

Jisook Lee

Miso Kim

Hyun Seon Kim

Scott L. Weinrich

Han Suk Ryu

Tae Yong Kim

Stephen Dann

Yu-Jin Kim

Diane R. Fernandez

Jiwon Koh

Shuoguo Wang

Song Yi Park

Shibing Deng

Eric Powell

Rupesh Kanchi Ravi

Jadwiga Bienkowska

Paul A. Rejto

Woong-Yang Park

Zhengyan Kan

机构：

[1] Samsung Medical Center,Department of Medicine

[2] Sungkyunkwan University School of Medicine,Department of Health Science and Technology, School of Medicine & SAIHST

[3] Sungkyunkwan University,Oncology Research & Development

[4] Seoul National University Hospital,Biostatistics

[5] Cancer Research Institute,Drug Safety R&D

[6] Seoul National University College of Medicine,Research Center for Future Medicine

[7] Seoul National University,undefined

[8] Samsung Genome Institute,undefined

[9] Samsung Medical Center,undefined

[10] Pfizer Inc,undefined

[11] Pfizer Inc,undefined

[12] Pfizer Inc,undefined

[13] Samsung Medical Center,undefined

[14] Pfizer Oncology,undefined

来源：

Genome Medicine | / 15卷

关键词：

Advanced breast cancer; Drug resistance; Genomic profile; Gene expression profiling; Palbociclib; Homologous recombination repair deficiengy (HRD);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
Park, Yeon Hee
Im, Seock-Ah
Park, Kyunghee
Wen, Ji
Lee, Kyung-Hun
Choi, Yoon-La
Lee, Won-Chul
Min, Ahrum
Bonato, Vinicius
Park, Seri
Ram, Sripad
Lee, Dae-Won
Kim, Ji-Yeon
Lee, Su Kyeong
Lee, Won-Woo
Lee, Jisook
Kim, Miso
Kim, Hyun Seon
Weinrich, Scott L.
Ryu, Han Suk
Kim, Tae Yong
Dann, Stephen
Kim, Yu-Jin
Fernandez, Diane R.
Koh, Jiwon
Wang, Shuoguo
Park, Song Yi
Deng, Shibing
Powell, Eric
Ravi, Rupesh Kanchi
Bienkowska, Jadwiga
Rejto, Paul A.
Park, Woong-Yang
Kan, Zhengyan
GENOME MEDICINE, 2023, 15 (01)
[2] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Esther S. Kim
Lesley J. Scott
Targeted Oncology, 2017, 12 : 373 - 383
[3] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Kim, Esther S.
Scott, Lesley J.
TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
[4] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Wang, Wei
Lei, Wenqian
Fang, Ziru
Jiang, Ruiyuan
Wang, Xiaojia
BMC CANCER, 2024, 24 (01)
[5] Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Wei Wang
Wenqian Lei
Ziru Fang
Ruiyuan Jiang
Xiaojia Wang
BMC Cancer, 24
[6] Systemic Therapy of HR-positive, HER2-negative metastatic Breast Cancer
Lorenz, Judith
GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 257 - 257
[7] Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
Nardin, Simone
Del Mastro, Lucia
ANNALS OF TRANSLATIONAL MEDICINE, 2023,
[8] Ribociclib in HR-positive, HER2-negative breast cancer
Burki, Talha Khan
LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
[9] Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
Pronzato, Paolo
FUTURE ONCOLOGY, 2017, 13 (16) : 1371 - 1384
[10] AN INCREMENTAL EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN PORTUGAL
Pinheiro, B.
Paquete, A. T.
Sousa, R.
Ines, M.
Gouveia, M.
Borges, M.
VALUE IN HEALTH, 2020, 23 : S529 - S529

← 1 2 3 4 5 →